Carcinogenic Mechanisms Related to Immunosuppressive Therapy

  • Conal M. Perrett
  • Catherine A. Harwood
  • Jane M. McGregor
  • Peter Karran
Part of the Cancer Treatment and Research book series (CTAR, volume 146)

Before 1985, azathioprine and corticosteroids were used to suppress the immune response and prevent allograft rejection in organ transplant recipients. Since 1985, the majority of patients have received cyclosporin in combination with azathoprine and/or corticosteroids. More recently, other immunosuppressive agents have been introduced, including tacrolimus, sirolimus, and mycophenolate mofetil [1-3], which are described elsewhere in this book (see Part I).


Transplant Recipient Skin Cancer Renal Transplant Recipient mTOR Inhibitor Mycophenolate Mofetil 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pouteil-Noble C. Immunosuppressive treatments. In: Euvrard S, Kanitakis J, Claudy A (eds) Skin Diseases After Organ Transplantation. Paris: John Libbey Eurotext, 1998:17–28.Google Scholar
  2. 2.
    Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002; 47:1–17.PubMedCrossRefGoogle Scholar
  3. 3.
    Kuypers DR. Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf 2005; 28(2):153–81.PubMedCrossRefGoogle Scholar
  4. 4.
    Morris JD, Eddleston AL, Crook T. Viral infection and cancer. Lancet 1995; 346(8977):754–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Glover MT, Deeks JJ, Raftery MJ et al. Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients. Lancet 1997; 349(9049):398PubMedCrossRefGoogle Scholar
  6. 6.
    Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370(9581):59–67.PubMedCrossRefGoogle Scholar
  7. 7.
    Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8(2):128–35.PubMedCrossRefGoogle Scholar
  8. 8.
    Luan FL, Hojo M, Maluccio M et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002; 73(10):1565–72.PubMedCrossRefGoogle Scholar
  9. 9.
    Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004; 18(4):446–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Ducloux D, Carron PL, Rebibou JM et al. CD4 lymphocytopenia as a risk factor for skin cancers in renal transplant recipients. Transplantation 1998; 65(9):1270–2.PubMedCrossRefGoogle Scholar
  11. 11.
    Gibson GE, O’Grady A, Kay EW et al. Langerhans cells in benign, premalignant and malignant skin lesions of renal transplant recipients and the effect of retinoid therapy. J Eur Acad Dermatol Venereol 1998; 10(2):130–1.PubMedCrossRefGoogle Scholar
  12. 12.
    Bergfelt L. Langerhans cells, immunomodulation and skin lesions. A quantitative, morphological and clinical study. Acta Derm Venereol Suppl (Stockh) 1993; 180:1–37.Google Scholar
  13. 13.
    Otley CC, Coldiron BM, Stasko T, Goldman GD. Decreased skin cancer after cessation of therapy with transplant-associated immunosuppressants. Arch Dermatol 2001; 137(4):459–63.PubMedGoogle Scholar
  14. 14.
    Glover MT, Niranjan N, Kwan JT, Leigh IM. Non-melanoma skin cancer in renal transplant recipients: the extent of the problem and a strategy for management. Br J Plast Surg 1994; 42(2):86–9.CrossRefGoogle Scholar
  15. 15.
    Jensen P, Hansen S, Moller B et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40(2 pt 1):177–86.PubMedCrossRefGoogle Scholar
  16. 16.
    Dantal J, Hourmant M, Cantarovich D et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two ciclosporin regimens. Lancet 1998; 351(9103):623–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Caforio AL, Fortina AB, Piaserico S et al. Skin cancer in heart transplant recipients: risk factor analysis and relevance of immunosuppressive therapy. Circulation 2000; 102(19 suppl 3):111222–7.Google Scholar
  18. 18.
    Chocair PR, Duley JA, Simmonds HA, Cameron JS. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 1992; 53(5):1051–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Ramsay HM, Harden PN, Reece S et al. Polymorphisms in glutathione S-transferases are associated with altered risk of nonmelanoma skin cancer in renal transplant recipients: a preliminary analysis. J Invest Dermatol 2001; 117(2):251–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Fryer AA, Ramsay HM, Lovatt TJ et al. Polymorphisms in glutathione S-transferases and non-melanoma skin cancer risk in Australian renal transplant recipients. Carcinogenesis (Oxf) 2005; 26(1):185–91.CrossRefGoogle Scholar
  21. 21.
    Karagas MR, Cushing GL Jr, Greenberg ER et al. Non-melanoma skin cancers and glucocorticoid therapy. Br J Cancer 2001; 85(5):683–6.PubMedCrossRefGoogle Scholar
  22. 22.
    IARC (International Agency for Research on Cancer). Monographs on the Evaluation of Carcinogenic Risk to Humans: Prednisone [446-86-6] 1987; 26(suppl 7):293Google Scholar
  23. 23.
    Kelly GE, Meikle W, Sheil AG. Effects of immunosuppressive therapy on the induction of skin tumors by ultraviolet irradiation in hairless mice. Transplantation 1987; 44(3):429–34.PubMedCrossRefGoogle Scholar
  24. 24.
    Paul CF, Ho VC, McGeown C et al. Risk of malignancies in psoriasis patients treated with ciclosporin: a 5 y cohort study. J Invest Dermatol 2003; 120(2):211–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Bunney MH, Benton EC, Barr BB et al. The prevalence of skin disorders in renal allograft recipients receiving ciclosporin A compared with those receiving azathioprine. Nephrol Dial Transplant 1990; 5(5):379–82.PubMedGoogle Scholar
  26. 26.
    Shuttleworth D, Marks R, Griffin PJ, Salaman JR. Epidermal dysplasia and ciclosporin therapy in renal transplant patients: a comparison with azathioprine. Br J Dermatol 1989; 120(4):551–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Herman M, Weinstein T, Korzets A et al. Effect of ciclosporin A on DNA repair and cancer incidence in kidney transplant recipients. J Lab Clin Med 2001; 137(1):14–20.PubMedCrossRefGoogle Scholar
  28. 28.
    Hiesse C, Larue JR, Kriaa F et al. Incidence and type of malignancies occurring after renal transplantation in conventionally and in ciclosporin-treated recipients: single-center analysis of a 20-year period in 1600 patients. Transplant Proc 1995; 27(4):2450–1.PubMedGoogle Scholar
  29. 29.
    IARC (International Agency for Research on Cancer). Monographs on the Evaluation of Carcinogenic Risk to Humans: Ciclosporin [79217-60-0] 1990; 50:77Google Scholar
  30. 30.
    Yarosh DB, Pena AV, Nay SL et al. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol 2005; 125(5):1020–5.PubMedCrossRefGoogle Scholar
  31. 31.
    Vamvakas S, Bahner U, Becker P et al. Impairment of DNA repair in the course of long-term hemodialysis and under ciclosporin immunosuppression after renal transplantation. Transplant Proc 1996; 28(6):3468–73.PubMedGoogle Scholar
  32. 32.
    Kelly GE, Meikle W, Sheil AG. Scheduled and unscheduled DNA synthesis in epidermal cells of hairless mice treated with immunosuppressive drugs and UVB-UVA irradiation. Br J Dermatol 1987; 117(4):429–40.PubMedCrossRefGoogle Scholar
  33. 33.
    Sugie N, Fujii N, Danno K. Cyclosporin-A suppresses p53-dependent repair DNA synthesis and apoptosis following ultraviolet-B irradiation. Photodermatol Photoimmunol Photomed 2002; 18(4):163–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Canning MT, Nay SL, Pena AV, Yarosh DB. Calcineurin inhibitors reduce nuclear localization of transcription factor NFAT in UV-irradiated keratinocytes and reduce DNA repair. J Mol Histol 2006; 37(5–7.):285–91.PubMedCrossRefGoogle Scholar
  35. 35.
    Queille S, Luron L, Spatz A et al. Analysis of skin cancer risk factors in immunosuppressed renal transplant patients shows high level of UV-specific tandem CC to TT mutations of the p53 gene. Carcinogenesis (Oxf) 2007; 28(3):724–31.CrossRefGoogle Scholar
  36. 36.
    Hojo M, Morimoto T, Maluccio M et al. Ciclosporin induces cancer progression by a cell-autonomous mechanism. Nature (Lond) 1999; 397(6719):530–4.CrossRefGoogle Scholar
  37. 37.
    Koranda FC, Loeffler RT, Koranda DM, Penn I. Accelerated induction of skin cancers by ultraviolet radiation in hairless mice treated with immunosuppressive agents. Surg Forum 1975; 26:145–6.PubMedGoogle Scholar
  38. 38.
    IARC (International Agency for Research on Cancer). Monographs on the Evaluation of Carcinogenic Risk to Humans: Azathioprine [446-86-6] 1987; 26(suppl 7):47Google Scholar
  39. 39.
    Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nat Rev Cancer 2001; 1: 99–108.PubMedCrossRefGoogle Scholar
  40. 40.
    Tidd DM, Paterson AR. A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 1974; 34(4):738–46.PubMedGoogle Scholar
  41. 41.
    Warren DJ, Andersen A, Slordal L. Quantitation of 6-thioguanine residues in peripheral blood leukocyte DNA obtained from patients receiving 6-mercaptopurine-based maintenance therapy. Cancer Res 1995; 55(8):1670–4.PubMedGoogle Scholar
  42. 42.
    Cuffari C, Seidman EG Latour S, Theoret Y. Quantitation of 6-thioguanine in peripheral blood leukocyte DNA in Crohn’s disease patients on maintenance 6-mercaptopurine therapy. Can J Physiol Pharmacol 1996; 74(5):580–5.PubMedCrossRefGoogle Scholar
  43. 43.
    Fairbanks LD, Bofill M, Ruckemann K, Simmonds HA. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J Biol Chem 1995; 270(50):29682–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Tiede I, Fritz G, Strand S et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111(8):1133–45.PubMedGoogle Scholar
  45. 45.
    Poppe D, Tiede I, Fritz G et al. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol 2006; 176(1):640–51.PubMedGoogle Scholar
  46. 46.
    Hemmens VJ, Moore DE. Photochemical sensitization by azathioprine and its metabolites. II. Azathioprine and nitroimidazole metabolites. Photochem Photobiol 1986; 43(3):257–62.PubMedCrossRefGoogle Scholar
  47. 47.
    O’Donovan P, Perrett CM, Zhang X et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309(5742):1871–4.PubMedCrossRefGoogle Scholar
  48. 48.
    Massey A, Xu YZ, Karran P. Photoactivation of DNA thiobases as a potential novel therapeutic option. Curr Biol 2001; 11(14);1142–6.PubMedCrossRefGoogle Scholar
  49. 49.
    Al-Tassan N, Chmiel NH, Maynard J et al. Inherited variants of MYH associated with somatic G : C → T: A mutations in colorectal tumors. Nat Genet 2002; 30(2):227–32.PubMedCrossRefGoogle Scholar
  50. 50.
    Euvrard S, Ulrich C, Lefrancois N. Immunosuppressants and skin cancer in transplant patients: focus on rapamycin. Dermatol Surg 2004; 30:628–33.PubMedCrossRefGoogle Scholar
  51. 51.
    de Fijter JW. Use of proliferation signal inhibitors in non melanoma skin cancer following renal transplantation. Nephrol Dial Transplant 2007; 22(suppl 1):123–6.Google Scholar
  52. 52.
    Sanchez-Fructuosu A, Conesa J, Perex Flores I, Ridao N et al. Conversion to sirolimus in renal transplant recipients with tumors. Transplant Proc 2006; 38(8):2451–2.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Conal M. Perrett
    • 1
  • Catherine A. Harwood
    • 2
    • 3
  • Jane M. McGregor
    • 4
  • Peter Karran
    • 5
  1. 1.Centre for Cutaneous Research, Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, Queen Mary, University of LondonLondonUK
  2. 2.Center for Cutaneous Research, Institute of Cell andMolecular Science, Barts and The London, School of Medicine and Dentistry, Queen Mary University of LondonLondon
  3. 3.Department of Dermatology, Barts and the London NHS TrustLondonUnited Kingdom
  4. 4.Center for Cutaneous Research, Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, Queen MaryUniversity of LondonLondonUnited Kingdom
  5. 5.Cancer Research UK, London Research Institute, Clare Hall LaboratoriesUnited Kingdom

Personalised recommendations